LEO Pharma has announced the sale of a portfolio of four non-core products to Cheplapharm for EUR 300 million.
The agreement represents a milestone in the roll-out of LEO Pharma’s 2030 strategy which increases the company’s focus on new innovative solutions for medical dermatology, it states.
“The divestment is an important step to strategically aligning our portfolio and increasing our focus on innovation in medical dermatology. Patients will be well served by Cheplapharm and we are confident that the company will be the right owner for this portfolio of well-established brands going forward,” says Catherine Mazzacco, President and CEO of LEO Pharma.
Products within bone disorders/nephrology, dermatology and gynecology
The divested portfolio comprises four products within bone disorders/nephrology, dermatology and gynecology: One-Alpha, Locoid, Pimafucin, and Zineryt. The annual turnover of the portfolio in 2019 amounted to approximately EUR 110 million.
The transaction is expected to close by December 2020.
Photo: LEO Pharma